CRLX101(NLG207) in Combination With Bevacizumab for Metastatic Renal Cell Carcinoma (mRCC) Versus Standard of Care (SOC)
Clinical trial NCT02187302 · COMPLETED
Trial details
- NCT number
- NCT02187302
- Sponsor
- NewLink Genetics Corporation
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2014-07-01
- Primary completion
- 2016-07-01
- Enrollment
- 115
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.